Amendments to the Claims

I. Amendments

Please amend claims 1 and 6 as indicated below.

II. The Claims of the Application

Claim 1. (**Currently amended**) A method of treating a focal muscle spasm, comprising administering, by intramuscular injection, a therapeutically effective dose of an immunotoxin conjugate to a muscle of said focal muscle spasm, wherein said immunotoxin conjugate comprises an antibody conjugated to a muscle toxin selected from the group consisting of: ricin and abrin, wherein said antibody is selectively reactive, under immunologically reactive conditions, to a nicotinic acetylcholine receptor ~~(nAchR)~~.

Claim 2. (**Original**) The method of claim 1, wherein the antibody is a monoclonal antibody.

Claim 3. (**Original**) The method of claim 1, wherein said mammalian acetylcholine receptor is a human acetylcholine receptor.

Claim 4. (**Currently amended**) The method of claim 1, wherein said muscle toxin is ricin.

Claim 5. (**Original**) The method of claim 1, wherein the focal muscle spasm is selected from the group consisting of: blepharospasm, cervical dystonia, hand dystonia, limb dystonia, hemifacial spasm, bruxism, strabismus, VI nerve palsy, spasmodic dysphonia, and oromandibular dystonia.

Claim 6. (**Currently amended**) A method of treating a focal muscle spasm, comprising administering, by intramuscular injection, a therapeutically

effective dose of an immunotoxin conjugate to a muscle of said focal muscle spasm, wherein said immunotoxin conjugate comprises an antibody conjugated to a galactose binding moiety and a muscle toxin selected from the group consisting of: ricin-A and abrin-A, wherein said antibody is selectively reactive, under immunologically reactive conditions, to a nicotinic acetylcholine receptor ~~(nAchR)~~.

Claim 7. (**Original**) The method of claim 6, wherein said galactose binding moiety is selected from the group consisting of: ricin-B and abrin-B.

Claim 8. (**Original**) The method of claim 6, wherein the antibody is a monoclonal antibody.

Claim 9. (**Original**) The method of claim 6, wherein said mammalian acetylcholine receptor is a human acetylcholine receptor.

Claim 10. (**Original**) The method of claim 6, wherein said toxin is ricin.

Claim 11. (**Original**) The method of claim 6, wherein the focal muscle spasm is selected from the group consisting of: blepharospasm, cervical dystonia, hand dystonia, limb dystonia, hemifacial spasm, bruxism, strabismus, VI nerve palsy, spasmodic dysphonia, and oromandibular dystonia.

Claim 12. (**Currently amended**) An immunotoxin conjugate, comprising an antibody conjugated to a muscle toxin selected from the group consisting of: ricin and abrin, wherein said antibody is selectively reactive, under immunologically reactive conditions, to a mammalian nicotinic acetylcholine receptor.

Claim 13. (**Original**) The immunotoxin of claim 12, wherein the antibody is a monoclonal antibody.

Claim 14. (**Original**) The immunotoxin conjugate of claim 12, wherein said mammalian acetylcholine receptor is a human acetylcholine receptor.

Claim 15. (**Currently amended**) The immunotoxin conjugate of claim 12, wherein said muscle toxin is ricin.